9/19/2022 2:01:41 AM
AbbVie Secures Positive CHMP Opinion For Risankizumab For Treatment Of Adults With Moderate To Severe Crohn's Disease
9/9/2022 10:29:54 AM
AbbVie Declares Quarterly Dividend Of $1.41/shr; Payable November 15/record October 14
9/9/2022 10:29:19 AM
AbbVie (ABBV) Declares Quarterly Dividend of $ 1.41, Record Date 10/14/2022
8/3/2022 8:49:11 AM
Allergan Aesthetics Announces FDA Approval Of JUVÉDERM VOLUX XC For Improvement Of Jawline Definition In Adults
7/29/2022 7:43:29 AM
AbbVie Q2 Adj. EPS Of $3.37, Increase Of 11.2%
7/29/2022 3:04:32 AM
AbbVie: EC Approves RINVOQ For Adults With Active Non-Radiographic Axial Spondyloarthritis
7/27/2022 8:51:46 AM
AbbVie Submits Regulatory Applications To FDA And EMA For Upadacitinib In Crohn's Disease
7/26/2022 2:07:42 AM
AbbVie : EU Approves RINVOQ For Treatment Of Adults With Moderate To Severe Ulcerative Colitis
7/20/2022 7:01:21 AM
AbbVie And ISTAR Medical Announce Alliance For Treatment Of Glaucoma